Literature DB >> 16751576

Overproduction of wild-type and bioengineered derivatives of the lantibiotic lacticin 3147.

Paul D Cotter1, Lorraine A Draper, Elaine M Lawton, Olivia McAuliffe, Colin Hill, R Paul Ross.   

Abstract

Lacticin 3147 is a broad-spectrum two-peptide lantibiotic whose genetic determinants are located on two divergent operons on the lactococcal plasmid pMRC01. Here we introduce each of 14 subclones, containing different combinations of lacticin 3147 genes, into MG1363 (pMRC01) and determine that a number of them can facilitate overproduction of the lantibiotic. Based on these studies it is apparent that while the provision of additional copies of genes encoding the biosynthetic/production machinery and the regulator LtnR is a requirement for high-level overproduction, the presence of additional copies of the structural genes (i.e., ltnA1A2) is not.

Mesh:

Substances:

Year:  2006        PMID: 16751576      PMCID: PMC1489664          DOI: 10.1128/AEM.02543-05

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  29 in total

1.  Regulation of immunity to the two-component lantibiotic, lacticin 3147, by the transcriptional repressor LtnR.

Authors:  O McAuliffe; T O'Keeffe; C Hill; R P Ross
Journal:  Mol Microbiol       Date:  2001-02       Impact factor: 3.501

Review 2.  Bacterial lantibiotics: strategies to improve therapeutic potential.

Authors:  Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Curr Protein Pept Sci       Date:  2005-02       Impact factor: 3.272

3.  Enhanced nisin production by increasing genes involved in nisin Z biosynthesis in Lactococcus lactis subsp. lactis A164.

Authors:  Chan-Ick Cheigh; Hoon Park; Hak-Jong Choi; Yu-Ryang Pyun
Journal:  Biotechnol Lett       Date:  2005-02       Impact factor: 2.461

4.  Identification of the Minimal Replicon of Lactococcus lactis subsp. lactis UC317 Plasmid pCI305.

Authors:  F Hayes; C Daly; G F Fitzgerald
Journal:  Appl Environ Microbiol       Date:  1990-01       Impact factor: 4.792

5.  Sequence and analysis of the 60 kb conjugative, bacteriocin-producing plasmid pMRC01 from Lactococcus lactis DPC3147.

Authors:  B A Dougherty; C Hill; J F Weidman; D R Richardson; J C Venter; R P Ross
Journal:  Mol Microbiol       Date:  1998-08       Impact factor: 3.501

6.  Molecular analysis of expression of the lantibiotic pep5 immunity phenotype.

Authors:  U Pag; C Heidrich; G Bierbaum; H G Sahl
Journal:  Appl Environ Microbiol       Date:  1999-02       Impact factor: 4.792

7.  Engineering Bacillus subtilis ATCC 6633 for improved production of the lantibiotic subtilin.

Authors:  Stefan Heinzmann; Karl-Dieter Entian; Torsten Stein
Journal:  Appl Microbiol Biotechnol       Date:  2005-07-07       Impact factor: 4.813

8.  Extensive post-translational modification, including serine to D-alanine conversion, in the two-component lantibiotic, lacticin 3147.

Authors:  M P Ryan; R W Jack; M Josten; H G Sahl; G Jung; R P Ross; C Hill
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

9.  Characterization of the nisin gene cluster nisABTCIPR of Lactococcus lactis. Requirement of expression of the nisA and nisI genes for development of immunity.

Authors:  O P Kuipers; M M Beerthuyzen; R J Siezen; W M De Vos
Journal:  Eur J Biochem       Date:  1993-08-15

10.  Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model.

Authors:  Danuta Kruszewska; Hans-Georg Sahl; Gabriele Bierbaum; Ulrike Pag; Sean O Hynes; Asa Ljungh
Journal:  J Antimicrob Chemother       Date:  2004-07-28       Impact factor: 5.790

View more
  9 in total

1.  Insertional mutagenesis to generate lantibiotic resistance in Lactococcus lactis.

Authors:  Caitriona M Guinane; Paul D Cotter; Elaine M Lawton; Colin Hill; R Paul Ross
Journal:  Appl Environ Microbiol       Date:  2007-05-25       Impact factor: 4.792

2.  Influence of Ca(2+) ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif.

Authors:  T Böttiger; T Schneider; B Martínez; H-G Sahl; I Wiedemann
Journal:  Appl Environ Microbiol       Date:  2009-05-08       Impact factor: 4.792

3.  Comparison of the Potency of the Lipid II Targeting Antimicrobials Nisin, Lacticin 3147 and Vancomycin Against Gram-Positive Bacteria.

Authors:  Catalin Iancu; Aoife Grainger; Des Field; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Probiotics Antimicrob Proteins       Date:  2012-06       Impact factor: 4.609

4.  Mechanistic dissection of the enzyme complexes involved in biosynthesis of lacticin 3147 and nisin.

Authors:  Anneke Kuipers; Jenny Meijer-Wierenga; Rick Rink; Leon D Kluskens; Gert N Moll
Journal:  Appl Environ Microbiol       Date:  2008-09-12       Impact factor: 4.792

5.  Influence of growth conditions on the nisin production of bioengineered Lactococcus lactis strains.

Authors:  O Simşek; A H Con; N Akkoç; P E J Saris; Mustafa Akçelik
Journal:  J Ind Microbiol Biotechnol       Date:  2009-01-10       Impact factor: 3.346

6.  Continuous nisin production with bioengineered Lactococcus lactis strains.

Authors:  O Simşek; N Akkoç; A H Con; F Ozçelik; P E J Saris; Mustafa Akçelik
Journal:  J Ind Microbiol Biotechnol       Date:  2009-04-01       Impact factor: 3.346

7.  Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V.

Authors:  Des Field; Lisa Quigley; Paula M O'Connor; Mary C Rea; Karen Daly; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Microb Biotechnol       Date:  2010-07       Impact factor: 5.813

8.  Identification and characterisation of capidermicin, a novel bacteriocin produced by Staphylococcus capitis.

Authors:  David Lynch; Paula M O'Connor; Paul D Cotter; Colin Hill; Des Field; Máire Begley
Journal:  PLoS One       Date:  2019-10-16       Impact factor: 3.240

9.  The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria.

Authors:  Lorraine A Draper; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  BMC Microbiol       Date:  2013-09-26       Impact factor: 3.605

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.